Sandoz submits BLA for breast and gastric cancer targeted biosimilar drug
Sandoz has submitted its Biologics License Application (BLA) for a proposed biosimilar trastuzumab developed by EirGenix, Inc to the US Food and Drug Administration (FDA).
Archives for December 21, 2021
Biogen halves price of Aduhelm in the US
As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.
NPD Gallery: Technology insider
What's new in biopharmaceutical manufacturing components and technology? We take a look.